These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

202 related items for PubMed ID: 24760752

  • 1. CD52 is a molecular target in advanced systemic mastocytosis.
    Hoermann G, Blatt K, Greiner G, Putz EM, Berger A, Herrmann H, Cerny-Reiterer S, Gleixner KV, Walz C, Hoetzenecker K, Müllauer L, Reiter A, Sotlar K, Sexl V, Valent P, Mayerhofer M.
    FASEB J; 2014 Aug; 28(8):3540-51. PubMed ID: 24760752
    [Abstract] [Full Text] [Related]

  • 2. CD52 is expressed on human mast cells and is a potential therapeutic target in Waldenstrom's Macroglobulinemia and mast cell disorders.
    Santos DD, Hatjiharissi E, Tournilhac O, Chemaly MZ, Leleu X, Xu L, Patterson C, Branagan AR, Manning RJ, Ho AW, Hunter ZR, Dimmock EA, Kutok JL, Churchill WH, Castells MC, Tai YT, Anderson KC, Treon SP.
    Clin Lymphoma Myeloma; 2006 May; 6(6):478-83. PubMed ID: 16796779
    [Abstract] [Full Text] [Related]

  • 3. Identification of campath-1 (CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML.
    Blatt K, Herrmann H, Hoermann G, Willmann M, Cerny-Reiterer S, Sadovnik I, Herndlhofer S, Streubel B, Rabitsch W, Sperr WR, Mayerhofer M, Rülicke T, Valent P.
    Clin Cancer Res; 2014 Jul 01; 20(13):3589-602. PubMed ID: 24799522
    [Abstract] [Full Text] [Related]

  • 4. Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis.
    Blatt K, Cerny-Reiterer S, Schwaab J, Sotlar K, Eisenwort G, Stefanzl G, Hoermann G, Mayerhofer M, Schneeweiss M, Knapp S, Rülicke T, Hadzijusufovic E, Bauer K, Smiljkovic D, Willmann M, Reiter A, Horny HP, Valent P.
    Blood; 2015 Dec 24; 126(26):2832-41. PubMed ID: 26486787
    [Abstract] [Full Text] [Related]

  • 5. CD52 antigen expressed by malignant plasma cells can be targeted by alemtuzumab in vivo in NOD/SCID mice.
    Carlo-Stella C, Guidetti A, Di Nicola M, Longoni P, Cleris L, Lavazza C, Milanesi M, Milani R, Carrabba M, Farina L, Formelli F, Gianni AM, Corradini P.
    Exp Hematol; 2006 Jun 24; 34(6):721-7. PubMed ID: 16728276
    [Abstract] [Full Text] [Related]

  • 6. A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents.
    Lapalombella R, Zhao X, Triantafillou G, Yu B, Jin Y, Lozanski G, Cheney C, Heerema N, Jarjoura D, Lehman A, Lee LJ, Marcucci G, Lee RJ, Caligiuri MA, Muthusamy N, Byrd JC.
    Clin Cancer Res; 2008 Jan 15; 14(2):569-78. PubMed ID: 18223233
    [Abstract] [Full Text] [Related]

  • 7. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD52 monoclonal antibody, Campath-1H.
    Zhang Z, Zhang M, Goldman CK, Ravetch JV, Waldmann TA.
    Cancer Res; 2003 Oct 01; 63(19):6453-7. PubMed ID: 14559836
    [Abstract] [Full Text] [Related]

  • 8. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
    Saito Y, Nakahata S, Yamakawa N, Kaneda K, Ichihara E, Suekane A, Morishita K.
    Leukemia; 2011 Jun 01; 25(6):921-31. PubMed ID: 21394097
    [Abstract] [Full Text] [Related]

  • 9. CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.
    Mueller N, Wicklein D, Eisenwort G, Jawhar M, Berger D, Stefanzl G, Greiner G, Boehm A, Kornauth C, Muellauer L, Sehner S, Hoermann G, Sperr WR, Staber PB, Jaeger U, Zuber J, Arock M, Schumacher U, Reiter A, Valent P.
    Blood; 2018 Nov 01; 132(18):1936-1950. PubMed ID: 30018080
    [Abstract] [Full Text] [Related]

  • 10. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
    Lee F, Luevano M, Veys P, Yong K, Madrigal A, Shaw BE, Saudemont A.
    PLoS One; 2014 Nov 01; 9(7):e103254. PubMed ID: 25050704
    [Abstract] [Full Text] [Related]

  • 11. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis.
    Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R.
    Pediatr Blood Cancer; 2005 Mar 01; 44(3):251-4. PubMed ID: 15390358
    [Abstract] [Full Text] [Related]

  • 12. A new humanized in vivo model of KIT D816V+ advanced systemic mastocytosis monitored using a secreted luciferase.
    Bibi S, Zhang Y, Hugonin C, Mangean MD, He L, Wedeh G, Launay JM, Van Rijn S, Würdinger T, Louache F, Arock M.
    Oncotarget; 2016 Dec 13; 7(50):82985-83000. PubMed ID: 27783996
    [Abstract] [Full Text] [Related]

  • 13. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.
    Aichberger KJ, Gleixner KV, Mirkina I, Cerny-Reiterer S, Peter B, Ferenc V, Kneidinger M, Baumgartner C, Mayerhofer M, Gruze A, Pickl WF, Sillaber C, Valent P.
    Blood; 2009 Dec 17; 114(26):5342-51. PubMed ID: 19850739
    [Abstract] [Full Text] [Related]

  • 14. In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V.
    Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valent P.
    Exp Hematol; 2010 Sep 17; 38(9):744-55. PubMed ID: 20553795
    [Abstract] [Full Text] [Related]

  • 15. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib.
    Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, Hadzijusufovic E, Meyer RA, Pickl WF, Gotlib J, Horny HP, Reiter A, Mitterbauer-Hohendanner G, Superti-Furga G, Valent P.
    Blood; 2011 Aug 18; 118(7):1885-98. PubMed ID: 21680801
    [Abstract] [Full Text] [Related]

  • 16. Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412.
    Aichberger KJ, Mayerhofer M, Gleixner KV, Krauth MT, Gruze A, Pickl WF, Wacheck V, Selzer E, Müllauer L, Agis H, Sillaber C, Valent P.
    Blood; 2007 Apr 01; 109(7):3031-41. PubMed ID: 17110460
    [Abstract] [Full Text] [Related]

  • 17. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies.
    Albitar M, Do KA, Johnson MM, Giles FJ, Jilani I, O'Brien S, Cortes J, Thomas D, Rassenti LZ, Kipps TJ, Kantarjian HM, Keating M.
    Cancer; 2004 Sep 01; 101(5):999-1008. PubMed ID: 15329909
    [Abstract] [Full Text] [Related]

  • 18. Effect of alemtuzumab on neoplastic B cells.
    Golay J, Manganini M, Rambaldi A, Introna M.
    Haematologica; 2004 Dec 01; 89(12):1476-83. PubMed ID: 15590398
    [Abstract] [Full Text] [Related]

  • 19. CD25 indicates the neoplastic phenotype of mast cells: a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens.
    Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P.
    Am J Surg Pathol; 2004 Oct 01; 28(10):1319-25. PubMed ID: 15371947
    [Abstract] [Full Text] [Related]

  • 20. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
    Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D.
    Leuk Res; 1998 Feb 01; 22(2):185-91. PubMed ID: 9593475
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.